Jonathan Hopper

Jonathan Hopper is Vice President, Platforms and founder of OMass Therapeutics, where he leads the development of native mass spectrometry–based technologies to interrogate protein interactions in physiologically relevant contexts. With a PhD in native MS and postdoctoral work at the University of Oxford, Jonathan has pioneered methods for studying challenging membrane protein assemblies and drug targets in near-native environments. As OMass’s first CEO, he guided the company through seed and Series A funding to build its in-house discovery engine. At the Summit, Jonathan will discuss bridging biophysics and physiology through native-context interaction mapping.